CHICAGO, Oct. 2 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. , a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation, will present four posters at the Infectious Diseases Society of America (IDSA) 45th Annual Meeting in San Diego, October 4-7. IDSA Annual Meetings typically feature cutting-edge, breakthrough science and provocative presentations on infectious diseases discoveries, treatments and cures.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGO)
This year, Advanced Life Sciences’ poster presentations will report data regarding the clinical safety and efficacy of cethromycin in selected human clinical trials including drug-drug interaction studies, oral suspension formulation studies and in pharyngitis/tonsillitis therapeutic studies in patients 12 years of age or older.
IDSA is an organization of physicians, scientists and other health care professionals who specialize in infectious diseases. Its purpose is to improve the health of individuals, communities, and society by promoting excellence in patient care, education, research, public health and prevention relating to infectious diseases. The Society was founded in 1963 and has approximately 8,000 members.
About Cethromycin
Advanced Life Sciences is developing cethromycin, a novel once-a-day antibiotic in response to the emerging bacterial resistance observed in the treatment of community acquired pneumonia (CAP). Cethromycin has been tested in approximately 5,000 human subjects during clinical trials.
The Company conducted two, pivotal Phase III clinical trials of cethromycin for the treatment of mild-to-moderate CAP. In June of 2007, Advanced Life Sciences released positive results from the first of these two trials, Trial CL-06, which showed that cethromycin met primary and secondary clinical endpoints. The Company expects data from the second trial, CL-05 to be reported in the Fall. The Company believes that cethromycin, if approved, would build upon the growing market opportunity in the antibiotic marketplace and address the critical need for antibiotics that overcome bacterial resistance.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company’s lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections. For more information, please visit us on the web at http://www.advancedlifesciences.com.
Forward-Looking Statements
Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences’ filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.
CONTACT: Joe Camp of Advanced Life Sciences Holdings, Inc.,
+1-630-754-4352; or media, Melanie Nimrodi, +1-312-546-3508, or investors,
Kathy Price, +1-213-486-6547, both of Financial Relations Board, for
Advanced Life Sciences Holdings, Inc.
Web site: http://www.advancedlifesciences.com/
